Trial Profile
Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2020
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Spinal cord injuries
- Focus Registrational; Therapeutic Use
- Sponsors Acorda Therapeutics
- 11 May 2014 New trial record